Wire · operational-macro
FDA Approves INOVIO's First DNA Immunotherapy for Rare Disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
The FDA has granted accelerated approval for INOVIO's VOCERYQ, the first plasmid DNA-based immunotherapy in the U.S., to reduce repeated surgeries in adults with recurrent respiratory papillomatosis. The approval marks a milestone for DNA medicine and requires a confirmatory clinical study by mid-2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
Biotech founders focusing on DNA therapies can now enter the US market with faster approval routes. Getting a firm clinical plan in place quickly will be critical as confirmatory trials are mandatory for ongoing approval.
◆ Coverage
9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics